Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
doi:10.3389/fimmu.2023.1246768 13
The inclusion of benzyl alcohol may help support multi-use handling scenarios within appropriate laboratory settings by reducing the risk of microbial contamination after initial opening
About ACHIEVE-2, ACHIEVE-5 and the ACHIEVE clinical trial program ACHIEVE-2 (NCT06192108) is a Phase 3, 40-week, randomized, active-controlled, open-label study comparing the efficacy and safety of orforglipron 3 mg, 12 mg and 36 mg to dapagliflozin 10 mg in participants with type 2 diabetes and inadequate glycemic control with metformin
You have tried first-line treatments such as metformin or other antidiabetic medications
Upon enrollment, you will have access to our team of professionals who will guide you through the process, offering personalized advice and support tailored to your individual needs
:max_bytes(150000):strip_icc()/Common-Symptoms-From-Taking-a-GLP-1-And-How-to-Manage-Them-9e5bb7cee0484522a50dd9d7ce954cc4.jpg)
US$ 21.67
US$ 24.47
US$ 28.29
